Real-World Evidence of Bevacizumab and Panitumumab Drug Resistance and Drug Ineffectiveness from EudraVigilance Database
by
, , , , , , and
Razvan Constantin Vonica
1, 
Claudiu Morgovan
1,*,
Anca Butuca
1,*
,
Manuela Pumnea
1,
Remus Calin Cipaian
2,3,
Adina Frum
1,
Carmen Maximiliana Dobrea
1,
Andreea Loredana Vonica-Tincu
1,
Aliteia-Maria Pacnejer
1,4,
Florina Batar
1,
Vlad Vornicu
5,
Steliana Ghibu
6 and
Felicia Gabriela Gligor
1
1
Preclinical Department, Faculty of Medicine, “Lucian Blaga” University of Sibiu, 550169 Sibiu, Romania
2
Clinical Department, Faculty of Medicine, “Lucian Blaga” University of Sibiu, 550169 Sibiu, Romania
3
County Clinical Emergency Hospital of Sibiu, 2-4 Corneliu Coposu Str., 550245 Sibiu, Romania
4
Department of Toxicology, Drug Industry, Management and Legislation, Faculty of Pharmacy, “Victor Babeş” University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania
5
Department IX Surgery, Discipline of Oncology, Faculty of Medicine, “Victor Babeş” University of Medicine and Pharmacy, 2nd Eftimie Murgu Sq., 300041 Timisoara, Romania
6
Department of Pharmacology, Physiology and Pathophysiology, Faculty of Pharmacy, “Iuliu Haţieganu” University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania
*
Authors to whom correspondence should be addressed.
Cancers 2025, 17(4), 663; https://doi.org/10.3390/cancers17040663
Submission received: 17 January 2025
/
Revised: 2 February 2025
/
Accepted: 14 February 2025
/
Published: 16 February 2025
(This article belongs to the Section Cancer Drug Development)
Simple Summary
Colorectal cancer is a leading cause of cancer-related deaths worldwide, and resistance to treatment poses a major challenge to patient survival. This study examines the effectiveness of two commonly used therapies—bevacizumab and panitumumab—in patients with advanced colorectal cancer. By analyzing reports of treatment failure and resistance from the European safety database, the study identifies patterns of reduced drug effectiveness. The findings show that a significant proportion of reported adverse reactions are related to resistance, with panitumumab having a higher likelihood of reported resistance than bevacizumab. These results emphasize the need for personalized treatment strategies based on a patient’s molecular profile. Monitoring drug resistance can help improve therapy selection and increase the chances of successful treatment, ultimately enhancing survival rates and quality of life for patients with colorectal cancer.
Excerpt
Note: In lieu of an abstract, this is an excerpt from the first page.
Colorectal cancer (CRC) is the third most common cancer in the world, with an average 5-year overall survival (OS) rate of approximately 60% [...]
